# US 2014/0275419 A1 · Two-part, cyanoacrylate/cationically curable adhesive systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0275419 A1
- Document ID: US20140275419A1
- Status: Published application
- Kind: A1
- Application number: 13/833,494
- Filed: 2013-03-15
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Henkel Ireland Limited
- Applicants: Henkel Ireland Limited
- Inventors: Emer Ward; Susan Reilly; Patricia A. Hedderman; Rachel Hersee; Deborah A. Moore
- Web page: https://patentgrep.com/patent/US20140275419A1

## CPC

- C08F 222/322: {Alpha-cyano-acrylic acid ethyl ester, e.g. ethyl-2-cyanoacrylate}
- C09J 4/00: Adhesives based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond {; adhesives, based on monomers of macromolecular compounds of groups C09J183/00 - C09J183/16}
- C09J 135/04: Homopolymers or copolymers of nitriles (C09J135/06, C09J135/08 take precedence)
- C08F: MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C09J: ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES (preparation of glue or gelatine C09H)

## Abstract

Two part cyanoacrylate/cationically curable adhesive systems are provided.

## Claims

### Claim 1

A two part curable composition comprising:
(a) a first part comprising a cyanoacrylate component and a cationic catalyst; and
(b) a second part comprising a cationic curable component and an initiator component,
wherein when mixed together the cationic catalyst initiates cure of the cationic curable component.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the cyanoacrylate component comprises H2C═C(CN)—COOR, wherein R is selected from alkyl, alkoxyalkyl, cycloalkyl, alkenyl, aralkyl, aryl, allyl and haloalkyl groups.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the cationic catalyst comprises salts of lithium and metals from Group II of the Periodic Table, and non-nucleophilic acids.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the cationic catalyst is a non-nucleophilic acid having a pH of less than 1.0 when measured as a 10% by weight solution in water.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the cationic catalyst is a member selected from the group consisting of fluoroboric, fluoroarsenic, fluoroantimonic and fluorophosphoric acids; lithium tetrafluoroborate, calcium di-tetrafluoroborate, magnesium di-tetrafluoroborate, lithium hexafluorophosphate, calcium di-hexafluorophosphate, magnesium di-hexafluorophosphate, lithium hexafluoroantimonate and lithium hexafluoroarsenate; lanthanide triflate salts, aryl iodonium salts, aryl sulfonium salts, lanthanum triflate, ytterbium triflate, trimethoxyboroxine, trimethoxyboroxine-aluminum acetyl acetonate, amine-boron trihalide complexes, quaternary ammonium salts, quaternary phosphonium salts, tri-aryl sulfonium salts, di-aryl iodonium salts, and diazonium salts; trialkoxyboroxine curing agents; and combinations thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the cationic curable component is selected from an epoxy component, an episulfide component, an oxetane component, a vinyl ether component and combinations thereof.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the cationic curable component is an epoxy component selected from the group consisting of cycloaliphatic epoxy, aromatic epoxy, aliphatic epoxy and hydrogenated aromatic epoxy.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the epoxy component comprises a member selected from the group consisting of epoxy-functionalized hydrogenated bisphenol-A, bisphenol-F, bisphenol-E, bisphenol-S and biphenyl.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the first part is, housed in a first chamber of a dual chamber syringe and the second part is housed in a second chamber of the dual chamber syringe.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the first part further comprises phosphoric acid.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the second part further comprises at least one of a plasticizer, a filler and a toughener.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the toughener is a member selected from the group consisting of (1) (a) reaction products of the combination of ethylene, methyl acrylate and monomers having carboxylic acid cure sites, (2) (b) dipolymers of ethylene and methyl acrylate, (3) combinations of (a) and (b), (4) vinylidene chloride-acrylonitrile copolymers, (5) and vinyl chloride/vinyl acetate copolymer, (6) copolymers of polyethylene and polyvinyl acetate, and combinations thereof.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the first part and the second part are present in a ratio of about 1:1 by volume.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the first part and the second part are each housed in a separate chamber of a dual chambered container.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the initiator component is a member selected from the group consisting of heterocycles, pyridines, benzothiazoles, toluidines, and phenolics.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the initiator component is a member selected from the group consisting of 3,5-dibromopyridine, 3,5-dichloropyridine, N,N-dimethyl-p-toluidine, 2,2-dipyridyl disulphide, 5-chloro-2-methyl benzothiazole, 2-methyl-mercaptobenzothiazole, N,N-dihydroethyl-p-toluidine, t-butylbenzothiazole sulphonamide, 4-methyl-2,2-ditertiarybutylphenol and 4-methoxyphenol.
